Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Protein unfolding during reversed-phase chromatography: II. Role of salt type and ionic strength.

McNay JL, O'Connell JP, Fernandez EJ.

Biotechnol Bioeng. 2001 Nov;76(3):233-40.

PMID:
11668459
2.
3.

Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.

Brynne L, McNay JL, Schaefer HG, Swedberg K, Wiltse CG, Karlsson MO.

Br J Clin Pharmacol. 2001 Jan;51(1):35-43.

4.
5.

Peripheral dopamine receptors in cardiovascular therapy. The legacy of Leon Goldberg (1927-1989).

Kohli JD, McNay JL, Rajfer SI, Murphy MB.

Hypertension. 1991 May;17(5):700-6. No abstract available.

PMID:
2022412
6.

Captopril modifies the hemodynamic and neuroendocrine responses to sodium nitroprusside in hypertensive patients.

Clementi WA, Durst NL, McNay JL, Keeton TK.

Hypertension. 1986 Mar;8(3):229-37.

PMID:
3512428
7.

Effect of oral dose size on hydralazine kinetics and vasodepressor response.

Shepherd AM, Irvine NA, Ludden TM, Lin MS, McNay JL.

Clin Pharmacol Ther. 1984 Nov;36(5):595-600.

PMID:
6488679
8.

Activation of the renin-angiotensin system by sodium nitroprusside in essential hypertension.

Shepherd AM, Pinkley W, Lin MS, McNay JL, Keeton TK.

J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):201-5.

PMID:
6199605
9.

Effects of hydralazine and sodium nitroprusside on plasma catecholamines and heart rate.

Lin MS, McNay JL, Shepherd AM, Keeton TK.

Clin Pharmacol Ther. 1983 Oct;34(4):474-80.

PMID:
6617069
10.

The response of plasma catecholamines to intravenous labetalol: a comparison with sodium nitroprusside.

Lin MS, McNay JL, Shepherd AM, Keeton TK.

Clin Pharmacol Ther. 1983 Oct;34(4):466-73.

PMID:
6617068
11.

Effect of intravenous dose on hydralazine kinetics after administration.

Ludden TM, Shepherd AM, McNay JL Jr, Lin MS.

Clin Pharmacol Ther. 1983 Aug;34(2):148-52.

PMID:
6872407
12.
13.

Increased plasma norepinephrine accompanies persistent tachycardia after hydralazine.

Lin MS, McNay JL, Shepherd AM, Musgrave GE, Keeton TK.

Hypertension. 1983 Mar-Apr;5(2):257-63.

PMID:
6826216
14.

Baroreflex sensitivity modulates vasodepressor response to nitroprusside.

Shepherd AM, Lin MS, McNay JL, Musgrave GE, Keeton TK.

Hypertension. 1983 Jan-Feb;5(1):79-85.

PMID:
6848471
15.

Endogenous generation of hydralazine from labile hydralazine hydrazones.

Clementi WA, McNay JL, Talseth T, Haegele KD, Ludden TM, Musgrave GE.

J Pharmacol Exp Ther. 1982 Jul;222(1):159-65.

PMID:
7086698
16.

Clinical pharmacokinetics of hydralazine.

Ludden TM, McNay JL Jr, Shepherd AM, Lin MS.

Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. Review. No abstract available.

PMID:
7047041
17.
18.

Dose response studies with vasodilator antihypertensive drugs.

McNay JL.

Clin Exp Hypertens A. 1982;4(1-2):61-9.

PMID:
7074992
19.

Plasma noradrenaline as a measure of baroreflex sensitivity in hypertensive man.

Shepherd AM, Lin MS, Keeton TK, McNay JL.

Clin Sci (Lond). 1981 Dec;61 Suppl 7:165s-168s.

PMID:
7318317
20.

Plasma concentration and acetylator phenotype determine response to oral hydralazine.

Shepherd AM, McNay JL, Ludden TM, Lin MS, Musgrave GE.

Hypertension. 1981 Sep-Oct;3(5):580-5.

PMID:
7298112
21.

Variability of plasma hydralazine concentrations in male hypertensive patients.

Ludden TM, McNay JL Jr, Shepherd AM, Lin MS.

Arthritis Rheum. 1981 Aug;24(8):987-93.

PMID:
7284051
22.

Vasoconstriction limits to the use of the central ear artery pressure in conscious rabbits.

Talseth T, McNay JL, Ballinger K, Clementi WA, Shepherd AM.

Lab Anim. 1981 Jan;15(1):1-3. No abstract available.

PMID:
7265889
23.

Hydralazine kinetics after single and repeated oral doses.

Shepherd AM, Ludden TM, McNay JL, Lin MS.

Clin Pharmacol Ther. 1980 Dec;28(6):804-11.

PMID:
7438695
24.

Hydralazine kinetics in hypertensive patients after intravenous administration.

Ludden TM, Shepherd AM, McNay JL, Lin MS.

Clin Pharmacol Ther. 1980 Dec;28(6):736-42.

PMID:
7438689
25.

Route and rate of hydrallazine administration as determinants to its hypotensive effect in rabbits.

Talseth T, McNay JL, Clementi WA.

Clin Exp Pharmacol Physiol. 1980 Jul;7(4):403-6.

PMID:
7418274
26.
27.

Quantitative analysis of hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine.

Haegele KD, Skrdlant HB, Talseth T, McNay JL, Shepherd AM, Clementi WA.

J Chromatogr. 1980 Jan 4;187(1):171-9.

PMID:
7358814
28.

The clinical pharmacology of vasodilator antihypertensive drugs.

O'Malley K, O'Boyle C, Kelly JG, McNay JL, O'Brien ET.

Arch Int Pharmacodyn Ther. 1980;Suppl:95-103.

PMID:
7416880
29.

Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone.

Talseth T, Haegele KD, McNay JL, Skrdlant HB, Clementi WA, Shepherd AM.

J Pharmacol Exp Ther. 1979 Dec;211(3):509-13.

PMID:
512915
30.

High-pressure liquid chromatographic assay for hydralazine in human plasma.

Ludden TM, Goggin LK, McNay JL Jr, Haegele KD, Shepherd AM.

J Pharm Sci. 1979 Nov;68(11):1423-5.

PMID:
512893
31.

Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.

Shepherd AM, Ludden TM, Haegele KD, Talseth T, McNay JL.

Res Commun Chem Pathol Pharmacol. 1979 Oct;26(1):129-44.

PMID:
515498
32.

Initial experience of clinical pharmacology and clinical pharmacy interactions in a clinical pharmacokinetics consultation service.

Taylor JW, McLean AJ, Leonard RG, Ludden TM, Clibon U, du Souich BP, Harris SC, Lalka D, Talbert RL, Vicuna N, Walton CA, McNay JL.

J Clin Pharmacol. 1979 Jan;19(1):1-7. No abstract available.

PMID:
762251
33.

Impaired theophylline clearance in patients with cor pulmonale.

Vicuna N, McNay JL, Ludden TM, Schwertner H.

Br J Clin Pharmacol. 1979 Jan;7(1):33-7.

34.

Dose-dependent pharmacokinetic behavior of lidocaine in the conscious dog.

Vicuna N, Lalka D, Burrow SR, McLean AJ, du Souich P, McNay JL.

Res Commun Chem Pathol Pharmacol. 1978 Dec;22(3):485-91.

PMID:
734228
35.

Sulfadiazine handling in the rabbit. II. Mechanisms of nonlinear kinetics of elimination.

du Souich P, McLean AJ, Lalka D, Vicuna N, Chauhuri E, McNay JL.

J Pharmacol Exp Ther. 1978 Oct;207(1):228-35. No abstract available.

PMID:
702344
36.

Sulfadiazine handling in the rabbit. I. Pseudosaturation of N-acetyltransferase.

du Souich P, McLean AJ, Lalka D, Jenkins B, Haegele KD, McNay JL.

J Pharmacol Exp Ther. 1978 Oct;207(1):221-7. No abstract available.

PMID:
702343
37.

Study of in vitro effects of hydralazine metabolites--comparative evaluation of products of hydroxylation, hydrolysis and conjugation.

McLean AJ, du Souich P, Barron K, Carrier O, Haegele KD, McNay JL.

Arch Int Pharmacodyn Ther. 1978 Sep;235(1):19-25.

PMID:
736689
38.

Bupivacaine and other amide local anesthetics inhibit the hydrolysis of chloroprocaine by human serum.

Lalka D, Vicuna N, Burrow SR, Jones DJ, Ludden TM, Haegele KD, McNay JL.

Anesth Analg. 1978 Sep-Oct;57(5):534-9.

PMID:
568420
39.
40.

Interaction of hydralazine and hydrazone derivatives with contractile mechanisms in rabbit aortic smooth muscle.

McLean AJ, Barron K, du Souich P, Haegele KD, McNay JL, Carrier O, Briggs A.

J Pharmacol Exp Ther. 1978 May;205(2):418-25.

PMID:
641837
41.

Intrarenal mechanism for renal vasoconstriction resulting from stimulation of the ureter in the dog.

Robie NW, McNay JL.

Clin Exp Pharmacol Physiol. 1978 Jan-Feb;5(1):81-4.

PMID:
639361
42.

Comparative evaluation of the in vitro effects of hydralazine and hydralazine acetonide on arterial smooth muscle.

Barron K, Carrier O, Haegele KD, McLean AJ, McNay JL, Du Souich P.

Br J Pharmacol. 1977 Nov;61(3):345-9.

43.
44.

Pharmacology of the renal circulation.

McNay JL.

Am J Med. 1977 Apr;62(4):507-13.

PMID:
851121
45.

Individualization of phenytoin dosage regimens.

Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, Hoffman SF, Wallace JE, Lalka D, McNay JL.

Clin Pharmacol Ther. 1977 Mar;21(3):287-93.

PMID:
837647
46.

Comparative splanchnic blood flow effects of various vasodilator compounds.

Robie NW, McNay JL.

Circ Shock. 1977;4(1):69-78.

PMID:
923009
47.

Relationship of urinary furosemide excretion rate to natriuretic effect in experimental azotemia.

Rose HJ, Pruitt AW, Dayton PG, McNay JL.

J Pharmacol Exp Ther. 1976 Dec;199(3):490-7.

PMID:
994014
48.

Determination of hydralazine and its metabolites by gas chromatography-mass spectrometry.

Haegele KD, Skrdlant HB, Robie NW, Lalka D, McNay JL Jr.

J Chromatogr. 1976 Nov 3;126:517-34.

PMID:
977694
49.

Effect of experimental azotemia on renal clearance of furosemide in the dog.

Rose HJ, Pruitt AW, McNay JL.

J Pharmacol Exp Ther. 1976 Jan;196(1):238-47.

PMID:
1246013
50.

Effect of selected drugs on arterial pressure response to upright posture.

McNay JL.

Cardiology. 1976;61 suppl 1:249-54. Review.

PMID:
788908

Supplemental Content

Loading ...
Support Center